ARTICLE | Clinical News
AADvac1: Phase II started
July 11, 2016 7:00 AM UTC
Axon Neuroscience began the double-blind, placebo-controlled, European Phase II ADAMANT trial to evaluate subcutaneous AADvac1 given monthly for 6 months followed by 2 booster doses given in 6-month i...